Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 20 in Indian Adults
NCT05875727Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Prevnar 20 in pneumococcal disease, sponsored by Pfizer. Started Aug 2023; status: completed.
02
Drugs
Prevnar 20
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT05875727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05875727.